Cycloferon, 125 mg/ml 2 ml 5 pcs

Pharmacotherapeutic group: other immunostimulants.

ATX code: L03AX.

Pharmacological properties

Pharmacodynamics

CYCLOPHERON® is a low molecular weight interferon inducer, which determines a wide range of its biological activity (antiviral, immunomodulatory, anti-inflammatory, etc.).

The main interferon-producing cells after administration of CYCLOPHERON® preparation are macrophages, T- and B-lymphocytes. Depending on the type of infection there is a predominance of activity of one or another link of immunity. The drug induces high titers of interferon in organs and tissues containing lymphoid elements (spleen, liver, lungs), activates stem cells of bone marrow, stimulating the formation of granulocytes. CYCLOPHERON® activates T-lymphocytes and natural killer cells, normalizes the balance between subpopulations of T-helpers and T-suppressors. It increases activity of α-interferons.

CYCLOPHERON® shows antiviral activity against tick-borne encephalitis, influenza, herpes, cytomegalovirus, papilloma virus and other viruses. Preclinical studies have shown that the use of Cycloferon in the early stages of the infection process leads to a decrease in the viral load (virus titer) in lung tissues. It increases nonspecific resistance of the body against viral and bacterial infections.

The high effectiveness of the drug was found in the treatment of acute and chronic bacterial infections (neuroinfections, chlamydia) as a component of immunotherapy.

Pharmacokinetics

When administered the maximum allowable dose the maximum concentration in blood is reached after 1-2 hours, after 24 hours the drug is detected in trace amounts. It crosses the blood-brain barrier. Half-life period of the drug is 4-5 hours. CYCLOPHERON® has no cumulative properties. It does not accumulate in the tissues after prolonged use.

Indications

Colds, Osteoarthritis, Hepatitis, Flu, Immunodeficiency states, Chronic infections, Herpes, Intestinal infections, Infectious diseases, Rheumatoid arthritis

In adults in the complex therapy:

– herpes and cytomegalovirus infection;
– neuroinfections: serous meningitis and encephalitis, tick-borreliosis (Lyme disease);
– secondary immunodeficiencies associated with acute and chronic bacterial and fungal infections;
– chlamydial infections.

In children over 4 years of age in the complex therapy:

– in the complex therapy of herpetic infection.

.

Active ingredient

Meglumina acridonacetate

Composition

Active ingredient:

Meglumine acridonacetate in terms of acridonacetic acid 125.0 mg, obtained according to the following formula: Acridonacetic acid 125.0 mg Meglumine (N-methylglucamine) 96.3 mg

Excipient: Water for injections up to 1.0 ml

How to take, the dosage

In adults

CYCLOPHERON® is used intravenously or intramuscularly. For herpes and cytomegalovirus infection, the treatment course consists of 10 injections of the drug at 250 mg with an interval between injections of 48 hours (every other day). A single dose is 250 mg (1 ampoule). The course dose is 2.5 g. Treatment is most effective at the beginning of exacerbation of the disease.

In cases of neuroinfections the course of treatment consists of 12 injections of the drug in 250-500 mg with an interval between injections of 48 hours (every other day) in combination with etiotropic therapy. A single dose is 250-500 mg (1-2 ampoules). The course dose is 3.0-6.0 g. Repeated courses are given as needed. For immunodeficiency states the treatment course consists of 10 intramuscular injections of 250 mg with an interval between injections of 48 hours (every other day). A single dose is 250 mg (1 ampoule). The course dose is 2.5 g. The repeated course is carried out after 6-12 months.

In case of chlamydial infection, the course of treatment consists of 10 injections of the drug of 250 mg with an interval between injections of 48 hours (every other day). A single dose is 250 mg (1 ampoule). The course dose is 2.5 g. The course of treatment shall be repeated in 10-14 days. It is advisable to combine CYCLOPHERON® with antibiotics.

In children over 4 years of age

CYCLOPHERON® is administered intramuscularly or intravenously. The single dose is 6-10 mg per 1 kg of body weight.

In case of herpetic infection the course of treatment consists of 10 injections of the drug with an interval between injections of 48 hours (every other day). If the replicative activity of the virus is preserved, the treatment course is continued according to the maintenance scheme – the drug is injected once every three days for four weeks.

Interaction

CYCLOPHERON® is compatible and well combined with all drugs traditionally used in the treatment of these diseases (interferons, chemotherapeutic drugs, etc.). It enhances the effect of interferons and nucleoside analogues. Reduces the side effects of chemotherapy, interferon therapy.

Special Instructions

In case of thyroid disorders, consultation with an endocrinologist is necessary. The urine may turn violet-blue (luminescence). If the solution changes color and sediment is formed, the drug should not be used.

Impact on ability to drive vehicles, mechanisms CYCLOPHERON® has no effect on the ability to drive vehicles, mechanisms.

Contraindications

Pregnancy, breastfeeding, hypersensitivity to components of the drug, decompensated liver cirrhosis, children under 18 years of age (for all indications, except for “in the treatment of herpes infections”), children under 4 years of age (for “in the treatment of herpes infections”).

Side effects

According to the World Health Organization, adverse effects are classified according to the frequency of their development as follows:
– very frequent (≥ 1/10);
– frequent (≥ 1/100 – < 1/10);
– infrequent (≥ 1/1000 – < 1/100);
– rare (≥ 1/10000 – < 1/1000);
– very rare (< 1/10000);
– frequency is unknown (cannot be determined on the basis of available data).

General disorders and disorders at the injection site: very rare – chills, increased body temperature, pain and redness at the injection site. Skin and subcutaneous tissue disorders: very rarely – rash, urticaria. If any of the adverse effects mentioned in the instructions is aggravated or if you notice any other undesirable effects not stated in the instructions, please inform your doctor.

Pregnancy use

The drug is contraindicated in pregnancy and during breast-feeding.